These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Expression, adverse prognostic significance and therapeutic small molecule inhibition of Polo-like kinase 1 in multiple myeloma. Evans RP; Dueck G; Sidhu R; Ghosh S; Toman I; Loree J; Bahlis N; Klimowicz AC; Fung J; Jung M; Lai R; Pilarski LM; Belch AR; Reiman T Leuk Res; 2011 Dec; 35(12):1637-43. PubMed ID: 21816470 [TBL] [Abstract][Full Text] [Related]
24. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Baughn LB; Di Liberto M; Wu K; Toogood PL; Louie T; Gottschalk R; Niesvizky R; Cho H; Ely S; Moore MA; Chen-Kiang S Cancer Res; 2006 Aug; 66(15):7661-7. PubMed ID: 16885367 [TBL] [Abstract][Full Text] [Related]
25. Toward development of a novel NOD/SCID-based in vivo strategy to model multiple myeloma pathogenesis. Bueno C; Lopes LF; Greaves M; Menendez P Exp Hematol; 2007 Oct; 35(10):1477-8. PubMed ID: 17681665 [No Abstract] [Full Text] [Related]
26. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma. Munugalavadla V; Mariathasan S; Slaga D; Du C; Berry L; Del Rosario G; Yan Y; Boe M; Sun L; Friedman LS; Chesi M; Leif Bergsagel P; Ebens A Oncogene; 2014 Jan; 33(3):316-25. PubMed ID: 23318440 [TBL] [Abstract][Full Text] [Related]
27. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult t-cell leukemia. Zhang M; Zhang Z; Garmestani K; Goldman CK; Ravetch JV; Brechbiel MW; Carrasquillo JA; Waldmann TA Cancer Res; 2004 Aug; 64(16):5825-9. PubMed ID: 15313926 [TBL] [Abstract][Full Text] [Related]
28. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997 [TBL] [Abstract][Full Text] [Related]
29. Preventing and Repairing Myeloma Bone Disease by Combining Conventional Antiresorptive Treatment With a Bone Anabolic Agent in Murine Models. Paton-Hough J; Tazzyman S; Evans H; Lath D; Down JM; Green AC; Snowden JA; Chantry AD; Lawson MA J Bone Miner Res; 2019 May; 34(5):783-796. PubMed ID: 30320927 [TBL] [Abstract][Full Text] [Related]
30. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma. Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322 [TBL] [Abstract][Full Text] [Related]
31. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma. Gan ZY; Fitter S; Vandyke K; To LB; Zannettino AC; Martin SK Eur J Haematol; 2015 Apr; 94(4):343-54. PubMed ID: 25179233 [TBL] [Abstract][Full Text] [Related]
32. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Yaccoby S; Barlogie B; Epstein J Blood; 1998 Oct; 92(8):2908-13. PubMed ID: 9763577 [TBL] [Abstract][Full Text] [Related]
33. Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. Tassone P; Neri P; Burger R; Di Martino MT; Leone E; Amodio N; Caraglia M; Tagliaferri P Curr Cancer Drug Targets; 2012 Sep; 12(7):814-22. PubMed ID: 22671927 [TBL] [Abstract][Full Text] [Related]
34. The role of plasmin in the pathogenesis of murine multiple myeloma. Eiamboonsert S; Salama Y; Watarai H; Dhahri D; Tsuda Y; Okada Y; Hattori K; Heissig B Biochem Biophys Res Commun; 2017 Jun; 488(2):387-392. PubMed ID: 28501622 [TBL] [Abstract][Full Text] [Related]
35. Toward an effective targeted chemotherapy for multiple myeloma. Polson AG; Sliwkowski MX Clin Cancer Res; 2009 Jun; 15(12):3906-7. PubMed ID: 19509145 [TBL] [Abstract][Full Text] [Related]
36. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. Sordillo EM; Pearse RN Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579 [TBL] [Abstract][Full Text] [Related]
37. Anti-CD54 (ICAM-1) has antitumor activity in SCID mice with human myeloma cells. Huang YW; Richardson JA; Vitetta ES Cancer Res; 1995 Feb; 55(3):610-6. PubMed ID: 7834632 [TBL] [Abstract][Full Text] [Related]
38. Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma. Yang J; Cao Y; Hong S; Li H; Qian J; Kwak LW; Yi Q Clin Cancer Res; 2009 Feb; 15(3):951-9. PubMed ID: 19188166 [TBL] [Abstract][Full Text] [Related]